Lyme Vaccine

For immediate release
August 15, 2001, Houston, Texas
www.vaccineinjury.org
(HOUSTON, TEXAS-August 15, 2001)
The Williams Bailey Law Firm, L.L.P., (Houston, Texas) has assembled a strategic alliance of the leading law firms in the country to make people aware of the National Vaccine Injury Compensation Program ("NVICP") and vigorously prosecute vaccine injury claims on a number of different fronts" according to John Eddie Williams, Jr., Managing Partner. "We will be offering our clients a full service individualized approach to vaccine
injury claims; from filing and administering claims under the NVICP, to pursuing individual civil actions across the nation if the Program denies a claim or awards an inadequate amount of compensation for the adverse reactions suffered".
In 1986 Congress established the NVICP to compensate victims, protect vaccine manufacturers and health care personnel administering vaccines from liability resulting from vaccine related injuries and deaths. Even though the enabling legislation that created the NVICP requires the Secretary of the Department of Health and Human Services to "undertake reasonable efforts to inform the public of the availability of the Program", most parents, teachers, physicians, and even many attorneys, are unaware of the existence
of this program, let alone the three year (3 year) statute of limitations that may bar claims that are not timely filed. "The Secretary has obviously done very little, if anything to fulfill this directive, so we will," according to Jeff Sell, an attorney working with the William Bailey Law Firm.
The limitation provision buried within the NVICP states:
"a vaccine set forth in the Vaccine Injury Table which is administered after October 1, 1988, if a vaccine-related injury occurred as a result of the administration of such vaccine, no petition may be filed for compensation under the Program for such injury after the expiration of 36 months [48 months with respect to death claims] after the date of the occurrence of the first symptom or manifestation of onset or of the significant aggravation of
such injury." 42 USC Sec. 300aa-16.
The strategic "vaccine alliance" includes: Williams Bailey Law Firm, L.L.P. (Houston), Conway, Homer & Chin-Caplan, P.C. (Boston), Shoemaker & Horn (Vienna, VA), Blizzard & McCarthy (Houston) and Hitt, Patterson & Sell-- www.HittPattersonSell.com (Houston) and others. Some of these firms have for years specialized in representing individuals under the NVICP who have been injured by vaccinations.
End of news V1 #97

Law firm - Ury & Moskow http://www.urymoskow.com/LYMErix.htm LYMErix® A number of people who received the Lyme disease vaccine, LYMErix, have subsequently reported symptoms that are worse than those associated with the disease itself. A number of these individuals have incurable arthritis and/or neurological impairment. Many of these cases could have been avoided had the people first gone for a routine blood exam to see if they have a blood trait known as HLA-DR4+. These individuals are susceptible to developing "treatment-resistant" Lyme arthritis. Approximately one-third of the general population has this HLA-DR4+ trait. People with this blood trait are unable to formulate a defense to the active ingredients in the vaccine. In addition to people with this blood trait, persons previously infected with Lyme disease may also experience extreme reactions to LYMErix. It is believed that the Lyme disease is hyperactivated in these people, causing their symptoms to become more severe than they were with Lyme disease alone. The makers of LYMErix, SmithKline, failed to inform either the doctors, or the general public to be tested, that the subjects should be tested for this blood trait. They also failed to properly test the effects of the vaccine on people with a history of Lyme disease. Ury & Moskow is currently investigating reports on behalf of individuals who suffer from severe arthritis and/or neurological disorders occurring after receiving LYMErix®. If you or someone you know suffers from severe arthritis or neurological impairment after receiving this vaccine, contact us if you would like to learn more about your rights.

http://iai.asm.org/cgi/content/abstract/69/12/7800

Epidemiol Infect. 2007 Jan;135(1):1-8. Epub 2006 Aug 8.
The Lyme vaccine: a cautionary tale.

* Nigrovic LE,
* Thompson KM.

Division of Emergency Medicine, Children's Hospital Boston, Boston,
MA, USA.

People living in endemic areas acquire Lyme disease from the bite of
an infected tick. This infection, when diagnosed and treated early in
its course, usually responds well to antibiotic therapy. A minority of
patients develops more serious disease, particularly after a delay in
diagnosis or therapy, and sometimes chronic neurological, cardiac, or
rheumatological manifestations. In 1998, the FDA approved a new
recombinant Lyme vaccine, LYMErixtrade mark, which reduced new
infections in vaccinated adults by nearly 80%. Just 3 years later, the
manufacturer voluntarily withdrew its product from the market amidst
media coverage, fears of vaccine side-effects, and declining sales. This
paper reviews these events in detail and focuses on the public
communication of risks and benefits of the Lyme vaccine and important
lessons learned.

PMID: 16893489 [PubMed - in process]

To read the following article you will have to register with BioMedNet. It is a great service. The article is fantastic and I highly recommend you register and read it!

Lyme Vaccine and Disease Reactivation? http://www.medscape.com/Medscape/CNO/2001/LDF/Story.cfm?story_id=2245

Reporting an Adverse Event to a Vaccination
--------------------------------------------------------------------------------

A. If you participated in the vaccination trails you have no time limit to report an adverse event.

1) Report the event to the researcher that gave you the vaccination.
2) If the researcher is unavailable or refuses to take the report then report yourself to the Company that funded the trial for Connaught call Ken Guito 570-839-4212 for SmithKline call Paula Goldberg 215-751-6593.
3) If the company does not take your report then you can report yourself via the Vaccine Adverse Event Reporting System (VAERS) see instructions below.

B. If you received a vaccination after the trial you or your doctor can report the event directly through VAERS.

To report your adverse event you will need to obtain a VAERS form. There is a toll free VAERS info line 1-800-822-7967 or you can download a PDF file from
www.fda.gov/cber/vaers/report.htm.

For more information on the VAERS (including a CME article) go to
www.fda.gov/medwatch/articles.htm.